…
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; and CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and PDE4 inhibitor for the treatment of psychiatric, neuroinflammatory, and other disorders. Cerevel Therapeutics Holdings, Inc. was founded in 2018 and is headquartered in Cambridge, Massachusetts.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -351.35M | -225.33M | -152.17M | -128.34M | - |
| Net income | -351.51M | -222.45M | -152.14M | -128.39M | - |
| Selling general administrative | 87.59M | 58.24M | 45.81M | 33.17M | - |
| Reconciled depreciation | 4.90M | 2.73M | 0.40M | 0.18M | - |
| Ebit | -372.75M | -222.83M | -149.51M | -83.46M | -483.32M |
| Ebitda | -367.85M | -220.10M | -149.12M | -36.84M | - |
| Depreciation and amortization | 4.90M | 2.73M | 0.40M | 46.62M | - |
| Non operating income net other | 6.88M | -5.39M | -3.05M | - | - |
| Operating income | -367.85M | -220.10M | -149.12M | -83.46M | - |
| Other operating expenses | 367.85M | 220.10M | 149.12M | 83.46M | - |
| Interest expense | 9.62M | 0.16M | 2.65M | 91.32M | 0.00M |
| Tax provision | 0.16M | 0.00M | -0.02M | 0.04M | - |
| Interest income | 9.62M | 0.16M | 0.22M | 1.55M | - |
| Net interest income | 9.62M | 0.16M | 0.22M | 1.55M | - |
| Income tax expense | 0.16M | -2.89M | -0.02M | 0.04M | - |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M | - |
| Total operating expenses | 367.85M | 220.10M | 149.12M | 83.46M | - |
| Total other income expense net | 16.50M | -5.24M | -3.05M | -44.88M | - |
| Net income from continuing ops | -351.51M | -225.33M | -152.14M | -128.39M | - |
| Net income applicable to common shares | -351.51M | -225.33M | -148.27M | -128.39M | -463.64M |
| Preferred stock and other adjustments | - | - | -3.87M | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 1243.30M | 1017.82M | 688.92M | 445.27M | 120.81M |
| Other current assets | 10.68M | 13.62M | 12.33M | 6.94M | 0.07M |
| Total liab | 569.55M | 496.58M | 110.19M | 60.75M | 42.98M |
| Total stockholder equity | 673.75M | 521.24M | 578.73M | 384.52M | 77.82M |
| Deferred long term liab | - | 0.29M | 0.48M | - | 1.49M |
| Other current liab | 76.91M | 59.60M | 0.38M | 0.27M | 0.07M |
| Common stock | 0.02M | 0.02M | 0.01M | 0.01M | 0.01M |
| Capital stock | 0.02M | 0.02M | 0.01M | 0.01M | 0.01M |
| Retained earnings | -1400.60M | -967.75M | -616.24M | -390.91M | -244.30M |
| Other liab | - | - | 33.54M | 0.24M | 2.29M |
| Other assets | - | 4.76M | 6.93M | 6.09M | 6.24M |
| Cash | 990.97M | 136.52M | 193.02M | 383.62M | 79.55M |
| Total current liabilities | 92.18M | 72.56M | 42.54M | 29.55M | 14.88M |
| Current deferred revenue | - | - | 28.43M | 22.25M | 10.10M |
| Net debt | -510.19M | 230.15M | -156.47M | -350.62M | -51.14M |
| Short term debt | 3.40M | 2.90M | 2.44M | 2.04M | 2.59M |
| Short long term debt total | 480.78M | 366.67M | 36.55M | 33.01M | 28.41M |
| Other stockholder equity | 2072.55M | 1485.88M | 1195.94M | 775.42M | 322.12M |
| Property plant equipment | - | 27.47M | 51.70M | 48.62M | 27.49M |
| Total current assets | 1006.94M | 905.65M | 578.02M | 390.56M | 87.08M |
| Long term investments | 185.20M | 58.13M | 52.27M | - | - |
| Net tangible assets | - | 521.24M | 578.73M | 384.52M | 77.82M |
| Short term investments | 574.50M | 755.51M | 372.67M | - | - |
| Net receivables | 5.29M | 2.05M | 0.73M | - | - |
| Long term debt | 337.42M | 335.48M | - | - | - |
| Inventory | - | -2.05M | -0.73M | - | - |
| Accounts payable | 11.86M | 10.06M | 11.30M | 4.99M | 2.11M |
| Accumulated other comprehensive income | 1.77M | 3.10M | -0.99M | -0.08M | -0.18M |
| Common stock total equity | - | 0.02M | 0.01M | 0.01M | 0.01M |
| Retained earnings total equity | - | -967.75M | -616.24M | -390.91M | - |
| Non currrent assets other | 3.43M | 4.76M | 6.93M | 6.09M | 6.24M |
| Non current assets total | 236.36M | 112.17M | 110.90M | 54.71M | 33.73M |
| Capital lease obligations | 31.19M | 34.09M | 36.55M | 33.01M | 28.41M |
| Long term debt total | - | 335.48M | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -384.88M | -425.16M | -18.89M | -1.10M | -425.16M |
| Change to liabilities | 30.04M | 15.95M | 1.42M | 0.61M | 5.01M |
| Total cashflows from investing activities | -388.83M | -435.66M | -18.89M | -1.10M | -44.25M |
| Net borrowings | 353.13M | 15.41M | -1.78M | 334.77M | - |
| Total cash from financing activities | 623.19M | 423.60M | 440.83M | 60.06M | 454.20M |
| Change to operating activities | 28.83M | 8.26M | 16.29M | -0.26M | 2.48M |
| Net income | -351.51M | -225.33M | -152.14M | -128.39M | -463.64M |
| Change in cash | -58.83M | -190.60M | 304.14M | -11.76M | 381.77M |
| Begin period cash flow | 197.22M | 387.82M | 83.68M | 95.44M | 8.10M |
| End period cash flow | 138.39M | 197.22M | 387.82M | 83.68M | 95.44M |
| Total cash from operating activities | -293.19M | -178.55M | -117.80M | -70.72M | -28.18M |
| Issuance of capital stock | 238.26M | 328.25M | 0.00M | 60.06M | - |
| Depreciation | 4.90M | 2.73M | 0.40M | 0.18M | 0.08M |
| Other cashflows from investing activities | - | -435.66M | -435.66M | -435.66M | -435.66M |
| Sale purchase of stock | 251.31M | 383.71M | - | - | - |
| Other cashflows from financing activities | 384.93M | 95.35M | 435.31M | -1.10M | 440.83M |
| Change to netincome | 39.09M | 46.79M | 13.70M | 57.15M | 427.89M |
| Capital expenditures | 3.95M | 10.50M | 18.89M | 1.10M | 44.25M |
| Cash flows other operating | -9.87M | 0.26M | 11.31M | - | - |
| Cash and cash equivalents changes | -58.83M | -190.60M | 304.14M | - | - |
| Change in working capital | 28.06M | 15.54M | 17.71M | 0.34M | - |
| Stock based compensation | 38.78M | 23.94M | 10.52M | 8.31M | - |
| Other non cash items | -13.42M | 0.69M | 2.44M | 2.40M | - |
| Free cash flow | -297.14M | -189.05M | -136.69M | -71.82M | - |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|
| NVO Novo Nordisk A/S |
-1.06 2.73% |
37.81 | 41.58 | 31.15 | 2.13 | 32.99 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-5.64 1.08% |
515.02 | 30.22 | 24.27 | 10.36 | 6.50 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
- -% |
920.69 | 29.07 | 20.12 | 7.57 | 3.82 | 19.42 |
| ARGNF argenx SE |
- -% |
965.00 | 45.77 | 31.25 | 13.84 | 7.12 | 36.06 |
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; and CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and PDE4 inhibitor for the treatment of psychiatric, neuroinflammatory, and other disorders. Cerevel Therapeutics Holdings, Inc. was founded in 2018 and is headquartered in Cambridge, Massachusetts.
| Name | Title | Year Born |
|---|---|---|
| Dr. N. Anthony Coles Jr., M.P.H. | Exec. Chairman & CEO | 1960 |
| Mr. Abraham N. Ceesay M.B.A. | Pres | 1978 |
| Mr. Mark Bodenrader | Interim CFO, VP of Fin. & Chief Accounting Officer | 1973 |
| Mr. Scott M. Akamine J.D. | Chief Legal Officer & Corp. Sec. | 1985 |
| Dr. Ramiro Sanchez M.D. | Chief Medical Officer | 1961 |
| Dr. John J. Renger Ph.D. | Chief Scientific Officer | 1969 |
| Mr. Matthew Calistri | VP of Investor Relations | NA |
| Mr. Kenneth A. DiPietro | Chief HR Officer | 1959 |
| Ms. Kathleen Tregoning M.A. | Chief Corp. Affairs Officer | 1971 |
| Dr. N. Anthony Coles Jr., M.P.H. | Executive Chairman | 1960 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.